Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement) [Internet].

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

London: National Institute for Health and Clinical Excellence (UK); 2009 May.

2.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

3.

Liraglutide for the treatment of type 2 diabetes.

Shyangdan D, Cummins E, Royle P, Waugh N.

Health Technol Assess. 2011 May;15 Suppl 1:77-86. doi: 10.3310/hta15suppl1/09. Review.

4.

The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.

Garg SK.

Diabetes Technol Ther. 2010 Jan;12(1):11-24. doi: 10.1089/dia.2009.0127. Review.

PMID:
20082581
5.

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.

Russell S.

Int J Clin Pharm. 2013 Apr;35(2):159-72. doi: 10.1007/s11096-012-9729-9. Epub 2012 Dec 22. Review.

PMID:
23263796
6.

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.

Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh NR.

BMC Endocr Disord. 2010 Dec 9;10:20. doi: 10.1186/1472-6823-10-20.

7.

The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide.

Barnett AH.

Diabetes Obes Metab. 2012 Apr;14(4):304-14. doi: 10.1111/j.1463-1326.2011.01523.x. Epub 2011 Dec 22. Review.

8.

Glucagon-like peptide analogues for type 2 diabetes mellitus.

Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, Snaith A.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD006423. doi: 10.1002/14651858.CD006423.pub2. Review.

PMID:
21975753
9.

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

Madsbad S, Kielgast U, Asmar M, Deacon CF, Torekov SS, Holst JJ.

Diabetes Obes Metab. 2011 May;13(5):394-407. doi: 10.1111/j.1463-1326.2011.01357.x. Epub 2011 Jan 5. Review.

PMID:
21208359
10.

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Madsbad S, Krarup T, Deacon CF, Holst JJ.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414. Review.

PMID:
18542012
11.

Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].

Jonas D, Van Scoyoc E, Gerrald K, Wines R, Amick H, Triplette M, Runge T.

Portland (OR): Oregon Health & Science University; 2011 Feb.

12.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
13.

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide.

Gurung T, Shyangdan DS, O'Hare JP, Waugh N.

Diabetes Metab Syndr Obes. 2015 Aug 10;8:363-86. doi: 10.2147/DMSO.S34418. eCollection 2015. Review.

14.
15.

[Emerging GLP-1 analogues and dipeptidyl peptidase 4(DPP-4) inhibitors].

Ohsugi M.

Nihon Rinsho. 2011 May;69(5):895-901. Review. Japanese.

PMID:
21595278
16.

DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?

Halimi S.

Diabetes Metab. 2008 Feb;34 Suppl 2:S91-5. doi: 10.1016/S1262-3636(08)73400-1.

PMID:
18640591
17.

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Deacon CF, Mannucci E, Ahrén B.

Diabetes Obes Metab. 2012 Aug;14(8):762-7. doi: 10.1111/j.1463-1326.2012.01603.x. Epub 2012 Apr 24. Review.

PMID:
22471248
18.

Insulin detemir versus insulin glargine for type 2 diabetes mellitus.

Swinnen SG, Simon AC, Holleman F, Hoekstra JB, Devries JH.

Cochrane Database Syst Rev. 2011 Jul 6;(7):CD006383. doi: 10.1002/14651858.CD006383.pub2. Review.

PMID:
21735405
19.

Liraglutide: effects beyond glycaemic control in diabetes treatment.

McGill JB.

Int J Clin Pract Suppl. 2010 Oct;(167):28-34. doi: 10.1111/j.1742-1241.2010.02495.x. Review.

PMID:
20887302
20.

Incretin-based therapies in type 2 diabetes mellitus.

Chia CW, Egan JM.

J Clin Endocrinol Metab. 2008 Oct;93(10):3703-16. doi: 10.1210/jc.2007-2109. Epub 2008 Jul 15. Review.

Supplemental Content

Support Center